JPWO2020052631A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020052631A5
JPWO2020052631A5 JP2021513827A JP2021513827A JPWO2020052631A5 JP WO2020052631 A5 JPWO2020052631 A5 JP WO2020052631A5 JP 2021513827 A JP2021513827 A JP 2021513827A JP 2021513827 A JP2021513827 A JP 2021513827A JP WO2020052631 A5 JPWO2020052631 A5 JP WO2020052631A5
Authority
JP
Japan
Prior art keywords
triazolo
methyl
amino
alkyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513827A
Other languages
English (en)
Japanese (ja)
Other versions
JP7572353B2 (ja
JP2022500402A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/105591 external-priority patent/WO2020052631A1/en
Publication of JP2022500402A publication Critical patent/JP2022500402A/ja
Publication of JPWO2020052631A5 publication Critical patent/JPWO2020052631A5/ja
Priority to JP2024096058A priority Critical patent/JP2024123079A/ja
Application granted granted Critical
Publication of JP7572353B2 publication Critical patent/JP7572353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513827A 2018-09-12 2019-09-12 トリアゾロ-ピリミジン化合物およびそれらの使用 Active JP7572353B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024096058A JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ-ピリミジン化合物およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018105220 2018-09-12
CNPCT/CN2018/105220 2018-09-12
PCT/CN2019/105591 WO2020052631A1 (en) 2018-09-12 2019-09-12 Triazolo-pyrimidine compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024096058A Division JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ-ピリミジン化合物およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2022500402A JP2022500402A (ja) 2022-01-04
JPWO2020052631A5 true JPWO2020052631A5 (enExample) 2022-09-05
JP7572353B2 JP7572353B2 (ja) 2024-10-23

Family

ID=69778192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513827A Active JP7572353B2 (ja) 2018-09-12 2019-09-12 トリアゾロ-ピリミジン化合物およびそれらの使用
JP2024096058A Pending JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ-ピリミジン化合物およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024096058A Pending JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ-ピリミジン化合物およびそれらの使用

Country Status (12)

Country Link
US (2) US10858365B2 (enExample)
EP (1) EP3849983A4 (enExample)
JP (2) JP7572353B2 (enExample)
KR (1) KR102841843B1 (enExample)
CN (3) CN112279852B (enExample)
AR (1) AR116315A1 (enExample)
AU (1) AU2019340767B9 (enExample)
BR (1) BR112021004774A2 (enExample)
CA (1) CA3111869A1 (enExample)
MX (1) MX2021002998A (enExample)
TW (1) TWI820209B (enExample)
WO (1) WO2020052631A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066410B2 (en) * 2017-03-24 2021-07-20 3100 Central Expressway Llc Fused triazolo-pyrimidine compounds having useful pharmaceutical application
AU2018302179A1 (en) 2017-07-18 2020-02-13 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US20190292188A1 (en) * 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲(江蘇)醫藥股份有限公司 三唑并-嘧啶化合物及其用途
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CA3150766A1 (en) * 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2021156439A1 (en) 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物
CN117865963B (zh) * 2023-12-15 2026-02-24 上海凌凯科技股份有限公司 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2284737C (en) * 1997-03-24 2007-03-13 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]triazolo[1,5-c]pyrimidine derivatives
JPWO2002079204A1 (ja) 2001-03-28 2004-07-22 協和醗酵工業株式会社 8−チアゾリル[1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
AU2003272886A1 (en) 2002-09-24 2004-04-19 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
TWI812494B (zh) * 2017-01-20 2023-08-11 美商阿克思生物科學有限公司 用於治療癌症相關病症之唑嘧啶
RU2764655C2 (ru) * 2017-03-16 2022-01-19 Цзянсу Хэнжуй Медицин Ко., Лтд. ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
ES2919474T3 (es) * 2017-04-07 2022-07-26 Medshine Discovery Inc Derivado de [1,2,4]triazolo[1,5-c]pirimidina como inhibidor del receptor A2A
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
US20190292188A1 (en) * 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
DK3766884T3 (da) * 2018-04-28 2022-03-28 Medshine Discovery Inc Krystalform og salttype af triazolopyrimidinforbindelse og fremstillingsfremgangsmåde dertil
TWI820209B (zh) * 2018-09-12 2023-11-01 大陸商迪哲(江蘇)醫藥股份有限公司 三唑并-嘧啶化合物及其用途

Similar Documents

Publication Publication Date Title
CA2984259C (en) Combinations of inhibitors of irak4 with inhibitors of btk
KR102841843B1 (ko) 트리아졸로-피리미딘 화합물 및 그의 용도
JPWO2020052631A5 (enExample)
JP2013508404A5 (enExample)
JP2016500073A5 (enExample)
JP2012532931A5 (enExample)
JP2019504821A5 (enExample)
RU2018138050A (ru) Производные тиазолопиридина как агонисты gpr119
JP2013523884A5 (enExample)
JP2016500671A5 (enExample)
JP2016537384A5 (enExample)
JP2016522246A5 (enExample)
JP2012525395A5 (enExample)
JP2018536671A5 (enExample)
CA2570987A1 (en) Novel alkynyl derivatives as modulators of metabotropic glutamate receptors
JP2016529292A5 (enExample)
JP2016507551A5 (enExample)
JP2017500364A5 (enExample)
TW201927779A (zh) 作為PDE1抑制劑的1H-吡唑并[4,3-b]吡啶
JP2023145748A (ja) 新規トリアゾロン誘導体またはその塩、およびこれらを含む医薬組成物
US12275745B2 (en) Therapeutic compounds and methods of use
JP2018501209A5 (enExample)
US20190352302A1 (en) Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
WO2017157792A1 (en) Combinations of copanlisib
JP2020502230A5 (enExample)